• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Nominees for best AbbVie blunder in the last 10 years are…

Quote
Allergan acquisition and subsequent integration. We should have bought the products, keep some of sales teams but don’t bother with the rest.

Nobody cares for the whiners from Allergan and anyway they are dropping like flies now. Financially take the maximum win in synergies because you can’t absorb the innovation model while retrofitting it into AbbVie process built for very different business areas. This includes aesthetics. Almost 3 years of investment. What do we have to show for it other than diverting funding and focus from other therapeutic areas.

What is really going to come out of the pipeline now. The leaders who knew these areas from Allergan have left and the leaders left are new to the areas. Why not just have AbbVie leaders take it on then. At least they know how to navigate AbbVie. The conflict between the two cultures is a drain to both legacy organizations. How much is the Irvine site worth as a synergy?

Mark my words, the ROI into Allergan new product and strategy development at this point is a loss.
 
















The RDLT won this. Be it their productivity, the sheer hate they elicit from those they lead or their crappy personalities or the demeaning way they treat people. It will be on full display later this month.
 




anonymous said:
The RDLT won this. Be it their productivity, the sheer hate they elicit from those they lead or their crappy personalities or the demeaning way they treat people. It will be on full display later this month.
Click to expand...

Is there anyone on there except Tom who isn’t a hold over from Abbott?

I mean Abbott was self admittedly not good at developing drugs. It’s why they brought in everyone from Amgen initially.
 




anonymous said:
Is there anyone on there except Tom who isn’t a hold over from Abbott?

I mean Abbott was self admittedly not good at developing drugs. It’s why they brought in everyone from Amgen initially.
Click to expand...
So this is spot on. Now they did add two people from Allergan. Both not drug developers so they fit in nicely with the group.
 








anonymous said:
Isn't your ASL leader ex-Lilly? If so, also not a drug developer, medical affairs background who couldn't land an ASL position at Lilly.
Click to expand...

Also a dietician by training I believe. Maybe it doesn’t matter for project leadership. The politics in that whole function is next level.

Rupal is good. Not sure he will stay long. He could easily be CSO at a top company. Abbott 2.0 is going nowhere for awhile. Just going to buy stuff and flog it commercially.

It’s the model they know, but it’s not really too exciting for R&D innovation.
 




anonymous said:
Also a dietician by training I believe. Maybe it doesn’t matter for project leadership. The politics in that whole function is next level.

Rupal is good. Not sure he will stay long. He could easily be CSO at a top company. Abbott 2.0 is going nowhere for awhile. Just going to buy stuff and flog it commercially.

It’s the model they know, but it’s not really too exciting for R&D innovation.
Click to expand...
It does matter for project leadership. You can’t lead without credibility, you can’t manage what you don’t understand. Last I checked, the people who run hospitals are generally doctors.
 




Yeah but what about SZ’s answer at Tom’s town hall today? Nice throwing her own person under the bus - no accountability for any of her dumb decisions. I guess it’s better than being on a big screen and being asked about your favorite make up … what a joke of a crew. It is truly crazy that this lot of idiots manages billions of dollars of R&D money, Rick might as well us it for build a camp fire - nothing is coming from this bunch.
 




anonymous said:
Yeah but what about SZ’s answer at Tom’s town hall today? Nice throwing her own person under the bus - no accountability for any of her dumb decisions. I guess it’s better than being on a big screen and being asked about your favorite make up … what a joke of a crew. It is truly crazy that this lot of idiots manages billions of dollars of R&D money, Rick might as well us it for build a camp fire - nothing is coming from this bunch.
Click to expand...

Kiss up, punch down culture. So much time is spent there positioning oneself to avoid blame rather than solving problems. And last I checked that’s what science was about; solving problems.

This is the crew that is going to crack the code on solid tumors?
 




anonymous said:
Kiss up, punch down culture. So much time is spent there positioning oneself to avoid blame rather than solving problems. And last I checked that’s what science was about; solving problems.

This is the crew that is going to crack the code on solid tumors?
Click to expand...
I literally laughed out loud at the thought exercise about this crew solving solid tumors. This crew at best could maybe clean up solid waste at AP.
 








Contemporaneous Use Case for AbbVie Management stupidity
  • Acquire a valuable pipeline of CNS assets through legacy Allergan.
  • Proceed to subordinate all the scientists and professionals responsible for the research, development and commercialization to people who have never accomplished any of these things
  • Proceed to explain to these same scientists why they don’t know what they are doing and why they need to correct their wayward ways
  • Said scientist leave drip, drip, drip and replaced by AbbVie folks looking for the next opportunity
  • Replace therapeutic head with a jack of all trades DC - nice with no expertise developing drugs in this TA
And together these steps ensures that full integration into AbbVie is complete and no further drugs come forward. Bravo RDLT! At least consistent and predictable. Bunch of joker’s including RT and his wise leadership choices.
 




anonymous said:
Contemporaneous Use Case for AbbVie Management stupidity
  • Acquire a valuable pipeline of CNS assets through legacy Allergan.
  • Proceed to subordinate all the scientists and professionals responsible for the research, development and commercialization to people who have never accomplished any of these things
  • Proceed to explain to these same scientists why they don’t know what they are doing and why they need to correct their wayward ways
  • Said scientist leave drip, drip, drip and replaced by AbbVie folks looking for the next opportunity
  • Replace therapeutic head with a jack of all trades DC - nice with no expertise developing drugs in this TA
And together these steps ensures that full integration into AbbVie is complete and no further drugs come forward. Bravo RDLT! At least consistent and predictable. Bunch of joker’s including RT and his wise leadership choices.
Click to expand...

I think every TA development VP left or was moved at some point since the merger.

I haven’t seen that level of churn at an established company before.
 








anonymous said:
It’s interesting. I have never seen a group of people with such disregard and even contempt for actual subject matter expertise.
Click to expand...

You tend to see it in insecure management groups that fear (know) they “got to the top” through politics rather than actual talent or knowledge.

They also tend to be those that blame everyone around themselves, especially subordinates.

You don’t hire or promote the people that can point out “the emperor has no cloths”
 




anonymous said:
You tend to see it in insecure management groups that fear (know) they “got to the top” through politics rather than actual talent or knowledge.

They also tend to be those that blame everyone around themselves, especially subordinates.

You don’t hire or promote the people that can point out “the emperor has no cloths”
Click to expand...

Spoken like someone who knows AbbVie management well. There should be pressure on management now. Stock is down, The investments made in R&D and commercial are not providing the expected returns. The bleed of talent continues. At some point, the people who have made the decisions that brought AbbVie to this point will be held accountable.

The naked emperor is about to get arrested for public indecency!
 




anonymous said:
Spoken like someone who knows AbbVie management well. There should be pressure on management now. Stock is down, The investments made in R&D and commercial are not providing the expected returns. The bleed of talent continues. At some point, the people who have made the decisions that brought AbbVie to this point will be held accountable.

The naked emperor is about to get arrested for public indecency!
Click to expand...

One or two more bad quarters and the board is going to hold people accountable. “You said you had a plan for 2023-2025. We were told this for a decade. If this is the plan, then you are fired, because we are getting hammered.”

Then someone new is going to come in with a buzz saw and “make their mark according to their new vision.”

The alternative is a panic big acquisition to buy management time. There’s a lot of debt already though and the cash flow is drying up.

Companies that fail patent cliffs hard become vulnerable to takeovers. I have no idea what that market cap threshold is, but it may have been a major reason for the Allergan deal.
 




Top Bottom
Back
Quote